Controlled Trial of 3 4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome (LEMS)

Study Overview

The overall purpose is to provide children access to 3,4-DAP, which is not currently approved by the FDA for use in the United States.

Study Description

This study is designed to provide 3,4-DAP to patients with Lambert-Eaton Myasthenic Syndrome (LEMS) in attempt to improve their quality of life.

  • IRB Number: 1010002406
  • Research Study Identifier: TX1285
  • Principal Investigator: Robert Pascuzzi, MD

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

If you need assistance finding a study or if you have any questions, please email: or call us at (317) 278-2176